ZLD Stock Overview
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based medicines for the treatment of various medical conditions in Australia.
Zelira Therapeutics Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$1.81|
|52 Week High||AU$8.75|
|52 Week Low||AU$0.90|
|1 Month Change||-44.99%|
|3 Month Change||31.16%|
|1 Year Change||-75.37%|
|3 Year Change||-85.01%|
|5 Year Change||-87.69%|
|Change since IPO||-55.03%|
Recent News & Updates
Is Zelira Therapeutics (ASX:ZLD) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|ZLD||AU Pharmaceuticals||AU Market|
Return vs Industry: ZLD underperformed the Australian Pharmaceuticals industry which returned -10.7% over the past year.
Return vs Market: ZLD underperformed the Australian Market which returned -6.5% over the past year.
|ZLD Average Weekly Movement||23.8%|
|Pharmaceuticals Industry Average Movement||12.5%|
|Market Average Movement||10.6%|
|10% most volatile stocks in AU Market||17.9%|
|10% least volatile stocks in AU Market||4.6%|
Stable Share Price: ZLD is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 24% a week.
Volatility Over Time: ZLD's weekly volatility has increased from 16% to 24% over the past year.
About the Company
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based medicines for the treatment of various medical conditions in Australia. The company is also involved in a human clinical trial program focused on insomnia, autism, and opioid reduction; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer, as well as the potential for cannabinoid formulations to treat diabetes-associated cognitive decline. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia.
Zelira Therapeutics Limited Fundamentals Summary
|ZLD fundamental statistics|
Is ZLD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ZLD income statement (TTM)|
|Cost of Revenue||AU$862.50k|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.07|
|Net Profit Margin||-785.91%|
How did ZLD perform over the long term?See historical performance and comparison